Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report

doi:10.12998/wjcc.v11.i11.2528

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1807)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

WORD

HTML

972

Figures (1-1)

278

Sum=1366

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

128

Download

313

Sum=441

Apr 16, 2023 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Apr 16, 2023; 11(11): 2528-2534
Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2528

Open in New Tab Full Size Figure Download Figure

Figure 1 Trends of indicators related to prostate cancer. A: Trends of prostate-specific antigen (PSA), testosterone, and alkaline phosphatase levels during the entire treatment process; B: Variations of PSA level after cessation of androgen deprivation therapy and capecitabine plus oxaliplatin chemotherapy for rectal cancer. PSA: Prostate-specific antigen; T: Testosterone; ALP: Alkaline phosphatase; RP: Radical prostatectomy; ADT: Androgen deprivation therapy; RRR: Radical rectal resection; CapeOx: Capecitabine plus oxaliplatin.

Citation: Zou Q, Shen RL, Guo X, Tang CY. Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report. World J Clin Cases 2023; 11(11): 2528-2534
URL: https://www.wjgnet.com/2307-8960/full/v11/i11/2528.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i11.2528